Filing an Investigational New Drug (IND) application can make or break a development program. For emerging biotech’s, regulatory missteps and unclear documentation can mean costly delays or even rejection.
In this 30-minute session, Syner-G’s experts share insider insights on FDA expectations, common pitfalls to avoid, and strategies to ensure your submission tells the right story the first time.
